Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 5/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 12/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20179699 | 0.80 | ELANE (0.38) | MEN1KMT2ACA2ELANE | |
| SCHEMBL19273587 | 0.79 | ELANE (0.44) | MEN1KMT2ACA2ELANE | |
| SCHEMBL20179712 | 0.77 | P2RX7 (0.35) | MEN1KMT2AP2RX7 | |
| SCHEMBL29756940 | 0.77 | P2RX7 (0.35) | MEN1KMT2AP2RX7 | |
| SCHEMBL24357327 | 0.77 | P2RX7 (0.39) | MEN1KMT2ACA2P2RX7SMN1; SMN2 | |
| SCHEMBL24362727 | 0.74 | P2RX7 (0.34) | MEN1KMT2AP2RX7 | |
| SCHEMBL19260389 | 0.74 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL19273758 | 0.73 | ELANE (0.44) | MEN1KMT2ACA2ELANE | |
| SCHEMBL30613266 | 0.72 | ELANE (0.37) | MEN1KMT2ACA2ELANE | |
| SCHEMBL26187600 | 0.72 | ELANE (0.37) | MEN1KMT2ACA2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-07 | — | — | US | disclosed |
| EP-3541809-B1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2025-06-25 | — | — | EP | disclosed |
| EP-4228758-B1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI SA (FR) | 2024-07-24 | — | — | EP | disclosed |
| US-20230382854-A1 | Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2023-11-30 | — | — | US | disclosed |
| EP-4228758-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2023-08-23 | — | — | EP | disclosed |
| CN-109963848-B | Substituted N- (3-fluoropropyl) -pyrrolidine compounds, preparation thereof and therapeutic use thereof | 赛诺菲 | 2022-07-05 | — | — | CN | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | SANOFI (FR) | 2022-06-30 | — | — | US | disclosed |
| WO-2022084280-A1 | SUBSTITUTED 6,7-DIHYDRO-5H-BENZO[7]ANNULENE COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2022-04-28 | — | — | WO | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2021-10-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT (FR) | 2020-11-19 | — | — | US | disclosed |
| EP-3541809-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | Sanofi (FR) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
| WO-2018091153-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200361918-A1 | NOVEL SUBSTITUTED N-(3-FLUOROPROPYL)-PYRROLIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | ESR1, CYP19A1, ESR2 | MEN1 4105/4885KMT2A 1252/4885CA2 2722/4885 |
| US-20230382854-A1 | Substituted 6,7-Dihydro-5H-Benzo[7]Annulene Compounds and Their Derivatives, Processes for Their Preparation and Therapeutic Uses Thereof | ESRRA, ESR2, FSHR | MEN1 2675/4885KMT2A 3745/4885CA2 1618/4885 |
| US-11149031-B2 | Substituted N-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | ESR1, CYP19A1, ESR2 | MEN1 4086/4885KMT2A 1216/4885CA2 2439/4885 |
| US-12595230-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | FSHR, CYP19A1, GPER1 | MEN1 3324/4885KMT2A 3756/4885CA2 1304/4885 |
| US-20220204488-A1 | Novel Substituted N-(3-Fluoropropyl)-Pyrrolidine Compounds, Processes for their Preparation and Therapeutic Uses Thereof | ESR1, CYP19A1, GPER1 | MEN1 3947/4885KMT2A 1127/4885CA2 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.